Pathogenesis of non-alcoholic fatty liver disease.
作者信息
Dowman J K, Tomlinson J W, Newsome P N
机构信息
Centre for Liver Research, Institute of Biomedical Research, University of Birmingham, B15 2TT, Birmingham, UK.
出版信息
QJM. 2010 Feb;103(2):71-83. doi: 10.1093/qjmed/hcp158. Epub 2009 Nov 13.
Abstract
摘要
相似文献
1
Pathogenesis of non-alcoholic fatty liver disease.
QJM. 2010 Feb;103(2):71-83. doi: 10.1093/qjmed/hcp158. Epub 2009 Nov 13.
2
New concepts in the pathogenesis of alcoholic liver disease.
Expert Rev Gastroenterol Hepatol. 2008 Dec;2(6):749-59. doi: 10.1586/17474124.2.6.749.
3
[Fatty liver and its clinical management in obese adolescents].
Endocrinol Nutr. 2011 Jan;58(1):32-7. doi: 10.1016/j.endonu.2010.10.005. Epub 2011 Jan 7.
4
Non-alcoholic steatohepatitis and metabolic syndrome.
Curr Opin Clin Nutr Metab Care. 2006 Sep;9(5):637-42. doi: 10.1097/01.mco.0000241677.40170.17.
5
Non-alcoholic steatohepatitis: pathogenesis and novel therapeutic approaches.
J Gastroenterol Hepatol. 2013 Aug;28 Suppl 1:68-76. doi: 10.1111/jgh.12212.
6
Review article: the pathogenesis of fibrosis in non-alcoholic steatohepatitis.
Aliment Pharmacol Ther. 2005 Nov;22 Suppl 2:44-7. doi: 10.1111/j.1365-2036.2005.02595.x.
7
Non-alcoholic fatty liver disease.
J Diabetes. 2012 Sep;4(3):266-80. doi: 10.1111/j.1753-0407.2012.00204.x.
8
Novel therapeutic targets for steatohepatitis.
Clin Res Hepatol Gastroenterol. 2015 Sep;39 Suppl 1:S46-50. doi: 10.1016/j.clinre.2015.05.012. Epub 2015 Jul 6.
9
Pathogenesis of non-alcoholic steatohepatitis: human data.
Clin Liver Dis. 2007 Feb;11(1):75-104, ix. doi: 10.1016/j.cld.2007.02.011.
10
Non-alcoholic fatty liver disease: further expression of the metabolic syndrome.
J Gastroenterol Hepatol. 2007 Mar;22(3):293-303. doi: 10.1111/j.1440-1746.2007.04824.x.
引用本文的文献
1
Targeting cAMP signaling and phosphodiesterase 4 for liver disease treatment.
Med Chem Res. 2024 Aug;33(8):1339-1353. doi: 10.1007/s00044-024-03267-3. Epub 2024 Jun 26.
2
Dynamic changes in macrophage populations and resulting alterations in Prostaglandin E sensitivity in mice with diet-induced MASH.
Cell Commun Signal. 2025 May 16;23(1):227. doi: 10.1186/s12964-025-02222-y.
3
The Role of Short-Chain Fatty Acids in Metabolic Dysfunction-Associated Steatotic Liver Disease and Other Metabolic Diseases.
Biomolecules. 2025 Mar 22;15(4):469. doi: 10.3390/biom15040469.
4
Substrates (Acyl-CoA and Diacylglycerol) Entry and Products (CoA and Triacylglycerol) Egress Pathways in DGAT1.
J Comput Chem. 2025 Apr 30;46(11):e70108. doi: 10.1002/jcc.70108.
5
Placenta nanoparticle treatment in guinea pigs mitigates FGR-associated fetal sex-dependent effects on liver metabolism-related signaling pathways.
Am J Physiol Endocrinol Metab. 2025 Mar 1;328(3):E395-E409. doi: 10.1152/ajpendo.00440.2024. Epub 2025 Feb 5.
6
In Vitro Evaluation of Probiotic Activities and Anti-Obesity Effects of EF-1 in Mice Fed a High-Fat Diet.
Foods. 2024 Dec 18;13(24):4095. doi: 10.3390/foods13244095.
7
Sex Hormone: A Potential Target at Treating Female Metabolic Dysfunction-Associated Steatotic Liver Disease?
J Clin Exp Hepatol. 2025 Mar-Apr;15(2):102459. doi: 10.1016/j.jceh.2024.102459. Epub 2024 Nov 19.
8
Quercetin: A Promising Candidate for the Management of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD).
Molecules. 2024 Nov 6;29(22):5245. doi: 10.3390/molecules29225245.
9
Prevalence of metabolic dysfunction-associated steatotic liver disease in people living with HIV and on antiretroviral treatment: A systematic review and meta-analysis protocol.
Health Sci Rep. 2024 Oct 28;7(11):e70071. doi: 10.1002/hsr2.70071. eCollection 2024 Nov.
10
Understanding Macrophage Complexity in Metabolic Dysfunction-Associated Steatotic Liver Disease: Transitioning from the M1/M2 Paradigm to Spatial Dynamics.
Livers. 2024 Sep;4(3):455-478. doi: 10.3390/livers4030033. Epub 2024 Sep 13.
本文引用的文献
1
A pilot study using simvastatin in the treatment of nonalcoholic steatohepatitis: A randomized placebo-controlled trial.
J Clin Gastroenterol. 2009 Nov-Dec;43(10):990-4. doi: 10.1097/MCG.0b013e31819c392e.
2
Serum adipokine levels predictive of liver injury in non-alcoholic fatty liver disease.
Liver Int. 2009 Oct;29(9):1431-8. doi: 10.1111/j.1478-3231.2009.02022.x. Epub 2009 Apr 24.
3
Hepatic progenitor cell-mediated regeneration and fibrosis: chicken or egg?
Hepatology. 2009 May;49(5):1424-6. doi: 10.1002/hep.22893.
4
GRP78 expression inhibits insulin and ER stress-induced SREBP-1c activation and reduces hepatic steatosis in mice.
J Clin Invest. 2009 May;119(5):1201-15. doi: 10.1172/JCI37007. Epub 2009 Apr 13.
5
Probiotics reduce the inflammatory response induced by a high-fat diet in the liver of young rats.
J Nutr. 2009 May;139(5):905-11. doi: 10.3945/jn.108.101808. Epub 2009 Mar 25.
6
Could inflammatory markers help diagnose nonalcoholic steatohepatitis?
Eur J Gastroenterol Hepatol. 2009 May;21(5):504-11. doi: 10.1097/MEG.0b013e3283229b40.
7
Overexpression of liver-specific cytochrome P4502E1 impairs hepatic insulin signaling in a transgenic mouse model of nonalcoholic fatty liver disease.
Eur J Gastroenterol Hepatol. 2009 Sep;21(9):973-83. doi: 10.1097/MEG.0b013e328328f461.
8
Angiotensin II activates I kappaB kinase phosphorylation of RelA at Ser 536 to promote myofibroblast survival and liver fibrosis.
Gastroenterology. 2009 Jun;136(7):2334-2344.e1. doi: 10.1053/j.gastro.2009.02.081. Epub 2009 Mar 18.
9
Association between angiotensin II type 1 receptor polymorphisms and the occurrence of nonalcoholic fatty liver disease.
Liver Int. 2009 Aug;29(7):1078-85. doi: 10.1111/j.1478-3231.2009.01988.x. Epub 2009 Mar 3.
10
Relation between liver progenitor cell expansion and extracellular matrix deposition in a CDE-induced murine model of chronic liver injury.
Hepatology. 2009 May;49(5):1625-35. doi: 10.1002/hep.22820.
Zotero 插件